Annals of the rheumatic diseases

• Latest
• Best
• Search…

• Ann. Rheum. Dis. · May 2020

  Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al.

  no abstract available

  keep going… or not…

• Ann. Rheum. Dis. · May 2020

  Letter

  Correspondence regarding research letter to the editor by Mathian et al, 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'.

  no abstract available

  expand abstract… or not…

• Ann. Rheum. Dis. · May 2020

  Response to: Correspondence regarding research letter to the editor by Mathian et al, 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour et al.

  no abstract available

  read on… mark as read…

• Ann. Rheum. Dis. · May 2020

  Letter

  Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.

  no abstract available

  keep reading… mark as read…

• Ann. Rheum. Dis. · May 2020

  Randomized Controlled Trial Multicenter Study

  Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.

  Bimekizumab selectively neutralises both interleukin (IL)-17A and IL-17F. We report efficacy and safety in a phase IIb dose-ranging study in patients with active ankylosing spondylitis (AS). ⋯ Bimekizumab provided rapid and sustained improvements in key outcome measures in patients with active AS, with no unexpected safety findings versus previous studies.

  keep reading… mark as read…